{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","name":"Research Synthesis: Exosomes Extracellular Vesicles — full paper","doi":"10.17605/OSF.IO/VTG79","doi_status":"minted","osf_url":"https://osf.io/vtg79/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_dbe570ea655e47b1/chain","content_hash":"sha256:8b3d52903329e950fc6e175396fc13a235a74e6cfd072bd35382832a98268c54","provenance_passport":{"publication_id":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","submission_id":"64376976-7a7c-4298-8d1a-61b9a07529f4","artifact_type":"research_paper","decision":"accept","content_hash":"sha256:8b3d52903329e950fc6e175396fc13a235a74e6cfd072bd35382832a98268c54","persistent_identifiers":{"doi":"10.17605/OSF.IO/VTG79","osf_url":"https://osf.io/vtg79/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":null,"provenance":{"dw_artifact_id":"claim_dbe570ea655e47b1","dw_chain_url":"https://provenance.researka.org/artifacts/claim_dbe570ea655e47b1/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","object_type":"publication","parent_object_id":"64376976-7a7c-4298-8d1a-61b9a07529f4","title":"Research Synthesis: Exosomes Extracellular Vesicles — full paper","body_markdown":"# Research Synthesis: Exosomes Extracellular Vesicles — full paper\n\n## Abstract\n\nThis paper synthesizes exosomes extracellular vesicles as an aging-related intervention across 56 included source papers and 2834 high-confidence extracted claims.\n\nThe evidence profile contains no sources classified primarily as direct clinical evidence, 26 adjacent clinical sources, and 3 mechanistic or model-system sources, with 668 cross-study disagreements across the evidence base.\n\nPositive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, safety and comorbidity and skeletal, fracture, and bone outcome classes, and negative signals in the immune outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.\n\nThe conclusion is that exosomes extracellular vesicles should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.\n\n## Methods\n\n### Review type and protocol\nThis manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-exosomes_extracellular_vesicles-v06-DAILY-2026-05-31T23-15-05Z`.\n\n### Information sources\nSources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-05-31.\n\n### Search strategy\nThe following topic-anchored queries were executed against the information sources listed above:\n\n- `exosomes AND aging AND human`\n- `extracellular vesicles AND skin aging`\n- `MSC exosomes AND clinical trial`\n- `exosome therapy AND safety`\n- `extracellular vesicles AND immune aging`\n\n### Eligibility criteria\n- Sources whose primary content addresses exosomes extracellular vesicles.\n- Sources with extractable quantitative or qualitative findings.\n- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.\n- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).\n\n### Selection of sources of evidence\nThe synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 191 records in the receipt-candidate union, 71 were classified as source candidates and 56 were admitted as traceable synthesis sources. No additional records were excluded after final source admission.\n\n### source admission funnel\n\n| Admission bucket | n |\n|---|---:|\n| Receipt candidate union | 191 |\n| Classified source candidates | 71 |\n| No extractable claims | 37 |\n| None-only claim binding | 15 |\n| Partial/none-only claim binding | 52 |\n| Partial-only candidates | 8 |\n| Strict high-confidence sources | 8 |\n| Admitted final sources | 56 |\n\n### Exclusion reasons\n- Non-traceable findings (claim could not be linked to source text): 0 records.\n- Wrong population / off-topic sources excluded at screening.\n- Duplicate records deduplicated by DOI / PMID before screening.\n\n### Data items\nThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Source verification in the public bundle is limited to reference-level metadata; reported statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.\n\n### Risk-of-bias appraisal\nPer-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.\n\n### Synthesis approach\nEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune, longevity, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.\n\n### AI-use disclosure\nSource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.\n\n### Accountability\nAccountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. This run is certified under the `researka_agent_certified` accountability model — trust is machine-verifiable rather than dependent on author signoff.\n\n## Results\n\n**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence.\n\n| Outcome class | Corpus slice | Strongest signal | Directness | Main limitation |\n|---|---|---|---|---|\n| Contextual Adjacent Evidence | n=36; claims=1715 | null signal in 33/36 sources | 18 indirect; 2 mechanistic; 16 review | limited corpus depth in this outcome class |\n| Immune | n=7; claims=165 | unclear signal in 2/7 sources | 2 indirect; 1 mechanistic; 4 review | limited corpus depth in this outcome class |\n| Safety and Comorbidity | n=6; claims=413 | null signal in 6/6 sources | 4 indirect; 2 review | limited corpus depth in this outcome class |\n| Skeletal, Fracture, and Bone | n=4; claims=142 | null signal in 4/4 sources | 4 review | limited corpus depth in this outcome class |\n| Cardiometabolic | n=1; claims=251 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n| Deficiency Prevalence | n=1; claims=9 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n| Longevity | n=1; claims=139 | mixed signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |\n\nThis evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.\n\n### Contextual Adjacent Evidence Outcomes\n\n36 included sources were assigned to this outcome class. Directional coding: null=33, positive=2, unclear=1. Directness coding: indirect=18, mechanistic=2, review=16.\n\n### Immune Outcomes\n\n7 included sources were assigned to this outcome class. Directional coding: mixed=2, negative=1, null=2, unclear=2. Directness coding: indirect=2, mechanistic=1, review=4.\n\n### Safety Comorbidity Outcomes\n\n6 included sources were assigned to this outcome class. Directional coding: null=6. Directness coding: indirect=4, review=2.\n\n### Skeletal Fracture Bone Outcomes\n\n4 included sources were assigned to this outcome class. Directional coding: null=4. Directness coding: review=4.\n\n### Cardiometabolic Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.\n\n### Deficiency Prevalence Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.\n\n### Longevity Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: mixed=1. Directness coding: review=1.\n\n## Limitations\n\n**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.\n\nA fundamental limitation of this synthesis is the composition of the curated evidence corpus. Although 56 papers were included, the majority are systematic reviews and meta-analyses of preclinical animal studies rather than primary human randomized controlled trials. For example, evidence for osteoporosis-related bone outcomes (Zhang 2025, He 2023, Zhang 2025b), periodontal regeneration (Zhou 2025), diabetic peripheral neuropathy (Lu 2025), and renal ischemia-reperfusion injury (Wang 2025) derives entirely from preclinical models.\n\nSeveral clinically important outcomes are represented by only a single study, precluding any within-corpus replication or assessment of consistency. The safety and efficacy of exosomes for knee osteoarthritis, assessed in Bolandnazar 2024 as a randomized, triple-blind, placebo-controlled trial, showed no statistically significant difference between EV-treated and placebo groups for clinical outcomes — yet this single null finding cannot be contextualized against other human trials because no other OA-specific RCT was included. Single-trial findings, whether positive or null, carry substantial uncertainty regarding reproducibility.\n\nThe enrolled populations across the included studies are narrow and raise external validity concerns. Only one observational study (Doi 2025) explicitly examined frail or sarcopenic adults with obstructive pulmonary disease, and that study focused on EV small-RNA profiles as biomarkers rather than therapeutic intervention. Consequently, the synthesis cannot directly address whether exosome-based therapies benefit older adults with age-related functional decline, and extrapolation from younger or comorbidity-specific cohorts remains speculative.\n\nThe corpus lacks long-term mortality and hard clinical endpoint data. No included study was designed with long-term survival as a primary endpoint in the aging-relevant population. The mechanism-to-clinic gap therefore remains wide: while preclinical data convincingly demonstrate anti-inflammatory and regenerative properties of EVs (Zhu 2025, Hong 2025), the translation to clinically meaningful, sustained benefit in older adults is not established by the available human evidence.\n\n## Conclusion\n\nFor exosomes extracellular vesicles, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support exosomes extracellular vesicles as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.\n\n## What This Synthesis Adds\n\nThis synthesis maps 56 included sources on Extracellular vesicles across 7 outcome classes and 668 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.\n\nAcross 56 curated reference papers, the evidence base for Extracellular vesicles shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: immune. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Extracellular vesicles anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.\n\nAdditional corpus sources included animal/preclinical evidence; the strongest unresolved contrast is the disagreement between Pineiro-Ramil 2025 and Hong 2025 on immune (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.\n\nAdditional corpus sources included animal/preclinical evidence; prior reviews in the corpus (Wu 2025, Wang 2025, Hong 2025, Wang 2025b, Su 2024) emphasize convergent signals on Extracellular vesicles. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.\n\n### Boundary-Condition Matrix\n\n| Outcome class | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |\n|---|---:|---:|---|---|\n| immune | 0 | 7 | mixed, negative, null, unclear | conflict-resolution gap |\n| longevity | 0 | 1 | mixed | direct clinical gap |\n| cardiometabolic | 0 | 1 | null | direct clinical gap |\n| contextual adjacent evidence | 0 | 36 | null, positive, unclear | direct clinical gap |\n| deficiency prevalence | 0 | 1 | null | direct clinical gap |\n| safety and comorbidity | 0 | 6 | null | direct clinical gap |\n| skeletal, fracture, and bone | 0 | 4 | null | direct clinical gap |\n\n### Evidence-Gap Priority\n\n| Priority | Gap | Rationale |\n|---|---|---|\n| P1 | immune: conflict-resolution gap | 0 direct and 7 indirect sources; direction profile: mixed, negative, null, unclear |\n| P2 | longevity: direct clinical gap | 0 direct and 1 indirect source; direction profile: mixed |\n| P3 | cardiometabolic: direct clinical gap | 0 direct and 1 indirect source; direction profile: null |\n| P4 | contextual adjacent evidence: direct clinical gap | 0 direct and 36 indirect sources; direction profile: null, positive, unclear |\n| P5 | deficiency prevalence: direct clinical gap | 0 direct and 1 indirect source; direction profile: null |\n\n### Next-Study Design Recommendation\n\nThe next high-yield study for Extracellular vesicles should target the **immune** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction.\n\n## Evidence Snapshot\n\nThe manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.\n\n### Load-Bearing Included Studies\n\nAdditional corpus sources included animal/preclinical evidence; - Wu 2025; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=longevity; direction=mixed; representative statistic=P = 0.0003.\n- Wang 2025; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=contextual other; direction=positive; representative statistic=P < 0.001.\n- Hong 2025; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=immune; direction=mixed; representative statistic=P < 0.00001.\n- Wang 2025b; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=contextual other; direction=positive; representative statistic=P < 0.00001.\n- Su 2024; Review / meta-analysis; tier=B1; directness=review; N=—; population=adults; endpoint=immune; direction=unclear.\n- Jafarzadeh 2025; Review / meta-analysis; tier=B2; directness=review; N=—; population=—; endpoint=contextual other; direction=null; representative statistic=P < 0.05.\n- Leung 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=cardiometabolic; direction=null; representative statistic=P = 0.0098.\n- Bolandnazar 2024; RCT; tier=B2; directness=indirect; N=—; population=adults; endpoint=safety comorbidity; direction=null.\n- Kishta 2025; RCT; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null; representative statistic=P = 0.001.\n- Behrangi 2026; Review / meta-analysis; tier=B2; directness=review; N=—; population=—; endpoint=safety comorbidity; direction=null; representative statistic=P < 0.001.\n\n### Load-Bearing Tensions\n\nAdditional corpus sources included animal/preclinical evidence; - Severity 4 disagreement: Pineiro-Ramil 2025 vs Hong 2025; Pineiro-Ramil 2025 (unclear) vs Hong 2025 (mixed) on immune\n- Severity 4 disagreement: Pineiro-Ramil 2025 vs Shi 2021; Pineiro-Ramil 2025 (unclear) vs Shi 2021 (mixed) on immune\n- Severity 4 disagreement: Hong 2025 vs Zeng 2025; Hong 2025 (mixed) vs Zeng 2025 (null) on immune\n- Severity 4 disagreement: Hong 2025 vs Pan 2025; Hong 2025 (mixed) vs Pan 2025 (negative) on immune\n- Severity 4 disagreement: Hong 2025 vs Dai 2026; Hong 2025 (mixed) vs Dai 2026 (null) on immune\n- Severity 4 disagreement: Hong 2025 vs Su 2024; Hong 2025 (mixed) vs Su 2024 (unclear) on immune\n- Severity 4 disagreement: Zeng 2025 vs Shi 2021; Zeng 2025 (null) vs Shi 2021 (mixed) on immune\n- Severity 4 disagreement: Pan 2025 vs Shi 2021; Pan 2025 (negative) vs Shi 2021 (mixed) on immune\n\nAdditional corpus sources included animal/preclinical evidence; additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Delen 2024, Ahmed 2024, Dhaliwal 2026, Luo 2024, Wei 2026, Zhang 2024, Andrews 2025, Bozbas 2024, Zamanian 2024, Kalluri 2025, Johnson 2023, Chernoff 2026, Jeppesen 2025, Ye 2024, Akhlaghpasand 2024, Santos 2026, Fang 2025, Kabatas 2025, Grueso-Navarro 2025, Habibi 2025, Wang 2025c, Hyun 2025, Estupinan 2025, Niu 2026, Civelek 2024, Zhu 2022, Li 2025, Svolacchia 2024, Ghanem 2025, Zhong 2023, Mitra 2026, Vreones 2022, Antoniewicz 2024, Su 2025.\n\n## References\n\n- **Jafarzadeh 2025.** _Effectiveness of regenerative medicine for skin lightening and rejuvenation: a systematic review of extracellular vesicles and conditioned media._ Stem Cell Research & Therapy, 2025. DOI: 10.1186/s13287-025-04592-z. PMID: 41013717.\n- **Leung 2025.** _Glycolytic control proteins in urinary extracellular vesicles are elevated during kidney transplant T cell-mediated rejection._ BMC Nephrology, 2025. DOI: 10.1186/s12882-025-04196-y. PMID: 40481420.\n- **Bolandnazar 2024.** _Safety and efficacy of placental mesenchymal stromal cells-derived extracellular vesicles in knee osteoarthritis: a randomized, triple-blind, placebo-controlled clinical trial._ BMC Musculoskeletal Disorders, 2024. DOI: 10.1186/s12891-024-07979-w. PMID: 39465400.\n- **Wu 2025.** _Efficacy and safety of mesenchymal stem/stromal cells and their derived extracellular vesicles for acute respiratory distress syndrome: a systematic review and meta-analysis._ Stem Cell Research & Therapy, 2025. DOI: 10.1186/s13287-025-04644-4. PMID: 41023747.\n- **Kishta 2025.** _The transforming role of wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial._ Stem Cell Research & Therapy, 2025. DOI: 10.1186/s13287-025-04690-y. PMID: 41084065.\n- **Behrangi 2026.** _A systematic review of clinical evidence on the efficacy and safety of conditioned media, platelet-rich fibrin, stromal vascular fraction, extracellular vesicles, and stem cells in androgenetic alopecia._ Stem Cell Research & Therapy, 2026. DOI: 10.1186/s13287-026-05016-2. PMID: 41987228.\n- **Zhu 2025.** _Mesenchymal stem cells-derived small extracellular vesicles and apoptotic extracellular vesicles for wound healing and skin regeneration: a systematic review and meta-analysis of preclinical studies._ Journal of Translational Medicine, 2025. DOI: 10.1186/s12967-024-05744-0. PMID: 40128791.\n- **Lu 2025.** _Cell-derived exosome therapy for diabetic peripheral neuropathy: a preclinical animal studies systematic review and meta-analysis._ Stem Cell Research & Therapy, 2025. DOI: 10.1186/s13287-025-04432-0. PMID: 40490808.\n- **Delen 2024.** _A systematic review and meta‐analysis of clinical trials assessing safety and efficacy of human extracellular vesicle‐based therapy._ Journal of Extracellular Vesicles, 2024. DOI: 10.1002/jev2.12458. PMID: 38958077.\n- **Wang 2025.** _Protective role of exosomes in renal ischemia-reperfusion injury: a systematic review and meta-analysis._ Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2025.1653907. PMID: 40978485.\n- **Zhou 2025.** _Therapeutic effect of mesenchymal stem cell-derived exosome therapy for periodontal regeneration: a systematic review and meta-analysis of preclinical trials._ Journal of Orthopaedic Surgery and Research, 2025. DOI: 10.1186/s13018-024-05403-6. PMID: 39780243.\n- **He 2023.** _Osteoporosis treatment using stem cell-derived exosomes: a systematic review and meta-analysis of preclinical studies._ Stem Cell Research & Therapy, 2023. DOI: 10.1186/s13287-023-03317-4. PMID: 37038180.\n- **Ahmed 2024.** _Stem Cell Extracellular Vesicles as Anti-SARS-CoV-2 Immunomodulatory Therapeutics: A Systematic Review of Clinical and Preclinical Studies._ Stem Cell Reviews and Reports, 2024. DOI: 10.1007/s12015-023-10675-2. PMID: 38393666.\n- **Dhaliwal 2026.** _The Use of Microneedling With Exosomes in Dermatology: A Systematic Review._ Journal of Cosmetic Dermatology, 2026. DOI: 10.1111/jocd.70881. PMID: 42027180.\n- **Hong 2025.** _Stem Cell-Derived Extracellular Vesicles for Acute Pancreatitis: a Systematic Review and Meta-analysis of Preclinical Studies._ Stem Cell Reviews and Reports, 2025. DOI: 10.1007/s12015-025-10852-5. PMID: 39964640.\n- **Luo 2024.** _Stem cell-derived extracellular vesicles in premature ovarian failure: an up-to-date meta-analysis of animal studies._ Journal of Ovarian Research, 2024. DOI: 10.1186/s13048-024-01489-y. PMID: 39252114.\n- **Shi 2021.** _Preclinical efficacy and clinical safety of clinical‐grade nebulized allogenic adipose mesenchymal stromal cells‐derived extracellular vesicles._ Journal of Extracellular Vesicles, 2021. DOI: 10.1002/jev2.12134. PMID: 34429860.\n- **Wang 2025b.** _Mesenchymal stem cell-derived exosomes for the treatment of knee osteoarthritis: a systematic review and meta-analysis based on rat model._ Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2025.1588841. PMID: 40529485.\n- **Pineiro-Ramil 2025.** _Mesenchymal stromal cells-derived extracellular vesicles in cartilage regeneration: potential and limitations._ Stem Cell Research & Therapy, 2025. DOI: 10.1186/s13287-025-04135-6. PMID: 39849578.\n- **Wei 2026.** _Therapeutic effects of stem cell–derived extracellular vesicles in animal models of intervertebral disc degeneration: a systematic review and meta-analysis of species differences and delivery strategies._ Frontiers in Bioengineering and Biotechnology, 2026. DOI: 10.3389/fbioe.2026.1749916. PMID: 41693926.\n- **Zhang 2024.** _The efficacy of extracellular vesicles for acute lung injury in preclinical animal models: a meta-analysis._ BMC Pulmonary Medicine, 2024. DOI: 10.1186/s12890-024-02910-4. PMID: 38481171.\n- **Andrews 2025.** _PSMA + Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts._ Clinical Cancer Research, 2025. DOI: 10.1158/1078-0432.CCR-24-3027. PMID: 39820657.\n- **Bozbas 2024.** _Dietary n-3 polyunsaturated fatty acids alter the number, fatty acid profile and coagulatory activity of circulating and platelet-derived extracellular vesicles: a randomized, controlled crossover trial._ The American Journal of Clinical Nutrition, 2024. DOI: 10.1016/j.ajcnut.2024.03.008. PMID: 38484976.\n- **Zhang 2025.** _Therapeutic effects of mesenchymal stem cell-derived extracellular vesicles in osteoporosis models: a systematic review and meta-analysis of preclinical studies._ Frontiers in Endocrinology, 2025. DOI: 10.3389/fendo.2025.1625969. PMID: 41036147.\n- **Zamanian 2024.** _Human placental mesenchymal stromal cell‐derived small extracellular vesicles as a treatment for severe COVID‐19: A double‐blind randomized controlled clinical trial._ Journal of Extracellular Vesicles, 2024. DOI: 10.1002/jev2.12492. PMID: 39051747.\n- **Kalluri 2025.** _Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates._ Nature Communications, 2025. DOI: 10.1038/s41467-025-63718-2. PMID: 41027940.\n- **Johnson 2023.** _First‐in‐human clinical trial of allogeneic, platelet‐derived extracellular vesicles as a potential therapeutic for delayed wound healing._ Journal of Extracellular Vesicles, 2023. DOI: 10.1002/jev2.12332. PMID: 37353884.\n- **Chernoff 2026.** _Human Placental Mesenchymal Stem Cell-Derived Exosomes in Wound Healing and Scar Therapy: A Systematic Review and Meta-analysis._ Aesthetic Surgery Journal, 2026. DOI: 10.1093/asj/sjaf163. PMID: 41800724.\n- **Jeppesen 2025.** _Blebbisomes are large, organelle-rich extracellular vesicles with cell-like properties._ Nature Cell Biology, 2025. DOI: 10.1038/s41556-025-01621-0. PMID: 39984653.\n- **Zhang 2025b.** _The effect of bone marrow mesenchymal stem cell-derived extracellular vesicles on bone mineral density and microstructure in osteoporosis: A systematic review and meta-analysis of preclinical studies._ PLOS One, 2025. DOI: 10.1371/journal.pone.0327011. PMID: 40587472.\n- **Ye 2024.** _Repair of spinal cord injury by bone marrow mesenchymal stem cell-derived exosomes: a systematic review and meta-analysis based on rat models._ Frontiers in Molecular Neuroscience, 2024. DOI: 10.3389/fnmol.2024.1448777. PMID: 39169950.\n- **Akhlaghpasand 2024.** _Safety and potential effects of intrathecal injection of allogeneic human umbilical cord mesenchymal stem cell-derived exosomes in complete subacute spinal cord injury: a first-in-human, single-arm, open-label, phase I clinical trial._ Stem Cell Research & Therapy, 2024. DOI: 10.1186/s13287-024-03868-0. PMID: 39183334.\n- **Santos 2026.** _The Effect of Cigarettes and E-Cigarettes on Epithelial-Derived Extracellular Vesicles: A Systematic Review._ International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27062787. PMID: 41898645.\n- **Fang 2025.** _Extracellular vesicles from bronchoalveolar lavage fluid provide insights into the inhaled corticosteroids treatment response in COPD._ Respiratory Research, 2025. DOI: 10.1186/s12931-025-03330-6. PMID: 40739568.\n- **Kabatas 2025.** _Efficacy and safety of exosomes from Wharton’s Jelly-derived mesenchymal stem cells in traumatic brain injury._ World Journal of Critical Care Medicine, 2025. DOI: 10.5492/wjccm.v14.i4.103782. PMID: 41377533.\n- **Grueso-Navarro 2025.** _MicroRNAs in Plasma-Derived Extracellular Vesicles as Non-Invasive Biomarkers for Eosinophilic Esophagitis._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26020639. PMID: 39859353.\n- **Habibi 2025.** _Efficacy of topical mesenchymal stem cell exosome in Sjögren’s syndrome-related dry eye: a randomized clinical trial._ BMC Ophthalmology, 2025. DOI: 10.1186/s12886-025-04078-9. PMID: 40394561.\n- **Wang 2025c.** _Injection of human umbilical cord mesenchymal stem cells exosomes for the treatment of knee osteoarthritis: from preclinical to clinical research._ Journal of Translational Medicine, 2025. DOI: 10.1186/s12967-025-06623-y. PMID: 40500748.\n- **Hyun 2025.** _Safety and Anti‐Inflammatory Effects of Engineered Extracellular Vesicles (ILB‐202) for NF‐κB Inhibition: A Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Trial._ Journal of Extracellular Vesicles, 2025. DOI: 10.1002/jev2.70141. PMID: 41002119.\n- **Estupinan 2025.** _Adipose Mesenchymal Stem Cell‐Derived Exosomes Versus Platelet‐Rich Plasma Treatment for Photoaged Facial Skin: An Investigator‐Blinded, Split‐Face, Non‐Inferiority Trial._ Journal of Cosmetic Dermatology, 2025. DOI: 10.1111/jocd.70208. PMID: 40414798.\n- **Pan 2025.** _Mesenchymal stem cell–derived small extracellular vesicles (sEVs) as a therapy for sepsis-related liver injury: evidence from a systematic review and meta-analysis._ Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2025.1707784. PMID: 41394125.\n- **Doi 2025.** _Small RNA Profiles of Serum-Derived Extracellular Vesicles in the Comorbid Condition of Frailty and Obstructive Pulmonary Disease: An Observational, Cross-Sectional Study._ Biomolecules, 2025. DOI: 10.3390/biom15121663. PMID: 41463319.\n- **Niu 2026.** _Altered circRNAs: a novel potential mechanism for the functions of extracellular vesicles derived from platelet-rich plasma._ Frontiers in Bioinformatics, 2026. DOI: 10.3389/fbinf.2025.1690932. PMID: 41584514.\n- **Civelek 2024.** _Effects of exosomes from mesenchymal stem cells on functional recovery of a patient with total radial nerve injury: A pilot study._ World Journal of Stem Cells, 2024. DOI: 10.4252/wjsc.v16.i1.19. PMID: 38292440.\n- **Zhu 2022.** _Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study._ Stem Cell Research & Therapy, 2022. DOI: 10.1186/s13287-022-02900-5. PMID: 35619189.\n- **Li 2025.** _Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment._ Signal Transduction and Targeted Therapy, 2025. DOI: 10.1038/s41392-025-02262-3. PMID: 40461474.\n- **Su 2024.** _Natural and bio-engineered stem cell-derived extracellular vesicles for spinal cord injury repair: A meta-analysis with trial sequential analysis._ Neuroscience, 2024. DOI: 10.1016/j.neuroscience.2024.10.018. PMID: 39490519.\n- **Svolacchia 2024.** _Exosomes and Signaling Nanovesicles from the Nanofiltration of Preconditioned Adipose Tissue with Skin-B ® in Tissue Regeneration and Antiaging: A Clinical Study and Case Report._ Medicina, 2024. DOI: 10.3390/medicina60040670. PMID: 38674316.\n- **Zeng 2025.** _MiRNA-loaded MSC exosomes restore autophagy flux for acute pancreatitis therapy._ Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1613716. PMID: 40842993.\n- **Ghanem 2025.** _Large extracellular vesicles (microvesicles) in diabetic nephropathy: a systematic review of preclinical studies._ Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2025.1622280. PMID: 41142249.\n- **Zhong 2023.** _Neural stem cell-derived exosomes and regeneration: cell-free therapeutic strategies for traumatic brain injury._ Stem Cell Research & Therapy, 2023. DOI: 10.1186/s13287-023-03409-1. PMID: 37553595.\n- **Mitra 2026.** _Effect of Glucoraphanin on the Abundance of Nrf2 Regulated Genes Within Circulating Small Extracellular Vesicles: A Pilot Dietary Intervention._ Molecular Nutrition & Food Research, 2026. DOI: 10.1002/mnfr.70397. PMID: 41603376.\n- **Vreones 2022.** _Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin._ Aging Cell, 2022. DOI: 10.1111/acel.13754. PMID: 36515353.\n- **Antoniewicz 2024.** _Vascular Stress Markers Following Inhalation of Heated Tobacco Products: A Study on Extracellular Vesicles._ Cardiovascular Toxicology, 2024. DOI: 10.1007/s12012-024-09934-6. PMID: 39472409.\n- **Su 2025.** _The role of synovial mesenchymal stem cell-derived exosomes in cartilage repair: a systematic review._ Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2025.1617874. PMID: 40635749.\n- **Dai 2026.** _Stem cell-derived exosomes in tissue regeneration of oral and maxillofacial region: A systematic review._ Medicine, 2026. DOI: 10.1097/MD.0000000000046948. PMID: 41496030.\n","metadata":{"abstract":"This paper synthesizes exosomes extracellular vesicles as an aging-related intervention across 56 included source papers and 2834 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct clinical evidence, 26 adjacent clinical sources, and 3 mechanistic or model-system sources, with 668 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, safety and comorbidity and skeletal, fracture, and bone outcome classes, and negative signals in the immune outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that exosomes extracellular vesicles should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","article_type":"rapid_evidence_synthesis","counts":{"retrieved_count":56,"selected_count":56,"review_like_count":27,"primary_like_count":29,"year_start":2021,"year_end":2026},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v3-full-paper-live","integrity":null,"identity_source":"api_key","authenticated_agent_id":"agent-v3-full-paper-live","doi":"10.17605/OSF.IO/VTG79","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"vtg79","osf_url":"https://osf.io/vtg79/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"vtg79","url":"https://osf.io/vtg79/","doi":"10.17605/OSF.IO/VTG79"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"dw_artifact_id":"claim_dbe570ea655e47b1","dw_chain_url":"https://provenance.researka.org/artifacts/claim_dbe570ea655e47b1/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_dbe570ea655e47b1/chain","dw_source_artifact_id":"source_71bf339cec954d8f","dw_input_artifact_ids":["source_dbec6bff8b1244df","source_c033809789b4470c","source_e2bcadb2aabe49b4","source_fcb30f2154634332","source_7ad299bc9c744805","source_2e6e8c82d8f04ee5"],"dw_step_id":"step_63ddb4a232944bfe","dw_step_hash":"027a5719f8c76673fde85809a07ec0cec8b71d6570de5c2f977ca7d9b3ebb172","dw_status":"registered","content_hash":"sha256:8b3d52903329e950fc6e175396fc13a235a74e6cfd072bd35382832a98268c54","sha256":"sha256:8b3d52903329e950fc6e175396fc13a235a74e6cfd072bd35382832a98268c54","osf_auth_source":"oauth_agent_token"},"created_at":"2026-06-01T03:18:59.371913+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","traces":[{"claim_id":"claim_1","claim":"The evidence profile contains no sources classified primarily as direct clinical evidence, 26 adjacent clinical sources, and 3 mechanistic or model-system sources, with 668 cross-study disagreements across the evidence base.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_2","claim":"Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, safety and comorbidity and skeletal, fracture, and bone outcome classes, and negative signals in the immune outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_3","claim":"The conclusion is that exosomes extracellular vesicles should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_4","claim":"This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-exosomes_extracellular_vesicles-v06-DAILY-2026-05-31T23-15-05Z`.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_5","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Source verification in the public bundle is limited to reference-level metadata; reported statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_6","claim":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_7","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune, longevity, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_8","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_9","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_10","claim":"| Contextual Adjacent Evidence | n=36; claims=1715 | null signal in 33/36 sources | 18 indirect; 2 mechanistic; 16 review | limited corpus depth in this outcome class |","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_11","claim":"| Safety and Comorbidity | n=6; claims=413 | null signal in 6/6 sources | 4 indirect; 2 review | limited corpus depth in this outcome class |","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_12","claim":"| Skeletal, Fracture, and Bone | n=4; claims=142 | null signal in 4/4 sources | 4 review | limited corpus depth in this outcome class |","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_13","claim":"| Cardiometabolic | n=1; claims=251 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_14","claim":"| Deficiency Prevalence | n=1; claims=9 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_15","claim":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_16","claim":"36 included sources were assigned to this outcome class. Directional coding: null=33, positive=2, unclear=1. Directness coding: indirect=18, mechanistic=2, review=16.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_17","claim":"7 included sources were assigned to this outcome class. Directional coding: mixed=2, negative=1, null=2, unclear=2. Directness coding: indirect=2, mechanistic=1, review=4.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_18","claim":"6 included sources were assigned to this outcome class. Directional coding: null=6. Directness coding: indirect=4, review=2.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_19","claim":"4 included sources were assigned to this outcome class. Directional coding: null=4. Directness coding: review=4.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_20","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_21","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_22","claim":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_23","claim":"A fundamental limitation of this synthesis is the composition of the curated evidence corpus. Although 56 papers were included, the majority are systematic reviews and meta-analyses of preclinical animal studies rather than primary human randomized controlled trials. For example, evidence for osteoporosis-related bone outcomes (Zhang 2025, He 2023, Zhang 2025b), periodontal regeneration (Zhou 2025), diabetic peripheral neuropathy (Lu 2025), and renal ischemia-reperfusion injury (Wang 2025) derives entirely from preclinical models.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_24","claim":"Several clinically important outcomes are represented by only a single study, precluding any within-corpus replication or assessment of consistency. The safety and efficacy of exosomes for knee osteoarthritis, assessed in Bolandnazar 2024 as a randomized, triple-blind, placebo-controlled trial, showed no statistically significant difference between EV-treated and placebo groups for clinical outcomes — yet this single null finding cannot be contextualized against other human trials because no other OA-specific RCT was included. Single-trial findings, whether positive or null, carry substantial uncertainty regarding reproducibility.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_25","claim":"The corpus lacks long-term mortality and hard clinical endpoint data. No included study was designed with long-term survival as a primary endpoint in the aging-relevant population. The mechanism-to-clinic gap therefore remains wide: while preclinical data convincingly demonstrate anti-inflammatory and regenerative properties of EVs (Zhu 2025, Hong 2025), the translation to clinically meaningful, sustained benefit in older adults is not established by the available human evidence.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_26","claim":"For exosomes extracellular vesicles, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support exosomes extracellular vesicles as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_27","claim":"This synthesis maps 56 included sources on Extracellular vesicles across 7 outcome classes and 668 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_28","claim":"Across 56 curated reference papers, the evidence base for Extracellular vesicles shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: immune. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Extracellular vesicles anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_29","claim":"Additional corpus sources included animal/preclinical evidence; the strongest unresolved contrast is the disagreement between Pineiro-Ramil 2025 and Hong 2025 on immune (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]},{"claim_id":"claim_30","claim":"Additional corpus sources included animal/preclinical evidence; prior reviews in the corpus (Wu 2025, Wang 2025, Hong 2025, Wang 2025b, Su 2024) emphasize convergent signals on Extracellular vesicles. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.","candidate_sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y"}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","content_hash":"sha256:8b3d52903329e950fc6e175396fc13a235a74e6cfd072bd35382832a98268c54","nodes":[{"id":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","type":"publication","title":"Research Synthesis: Exosomes Extracellular Vesicles — full paper"},{"id":"claim_1","type":"claim","text":"The evidence profile contains no sources classified primarily as direct clinical evidence, 26 adjacent clinical sources, and 3 mechanistic or model-system sources, with 668 cross-study disagreements across the evidence base."},{"id":"claim_2","type":"claim","text":"Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, safety and comorbidity and skeletal, fracture, and bone outcome classes, and negative signals in the immune outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect."},{"id":"claim_3","type":"claim","text":"The conclusion is that exosomes extracellular vesicles should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim."},{"id":"claim_4","type":"claim","text":"This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-exosomes_extracellular_vesicles-v06-DAILY-2026-05-31T23-15-05Z`."},{"id":"claim_5","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Source verification in the public bundle is limited to reference-level metadata; reported statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_6","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_7","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune, longevity, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_8","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_9","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence."},{"id":"claim_10","type":"claim","text":"| Contextual Adjacent Evidence | n=36; claims=1715 | null signal in 33/36 sources | 18 indirect; 2 mechanistic; 16 review | limited corpus depth in this outcome class |"},{"id":"claim_11","type":"claim","text":"| Safety and Comorbidity | n=6; claims=413 | null signal in 6/6 sources | 4 indirect; 2 review | limited corpus depth in this outcome class |"},{"id":"claim_12","type":"claim","text":"| Skeletal, Fracture, and Bone | n=4; claims=142 | null signal in 4/4 sources | 4 review | limited corpus depth in this outcome class |"},{"id":"claim_13","type":"claim","text":"| Cardiometabolic | n=1; claims=251 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |"},{"id":"claim_14","type":"claim","text":"| Deficiency Prevalence | n=1; claims=9 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |"},{"id":"claim_15","type":"claim","text":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate."},{"id":"claim_16","type":"claim","text":"36 included sources were assigned to this outcome class. Directional coding: null=33, positive=2, unclear=1. Directness coding: indirect=18, mechanistic=2, review=16."},{"id":"claim_17","type":"claim","text":"7 included sources were assigned to this outcome class. Directional coding: mixed=2, negative=1, null=2, unclear=2. Directness coding: indirect=2, mechanistic=1, review=4."},{"id":"claim_18","type":"claim","text":"6 included sources were assigned to this outcome class. Directional coding: null=6. Directness coding: indirect=4, review=2."},{"id":"claim_19","type":"claim","text":"4 included sources were assigned to this outcome class. Directional coding: null=4. Directness coding: review=4."},{"id":"claim_20","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_21","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_22","type":"claim","text":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim."},{"id":"claim_23","type":"claim","text":"A fundamental limitation of this synthesis is the composition of the curated evidence corpus. Although 56 papers were included, the majority are systematic reviews and meta-analyses of preclinical animal studies rather than primary human randomized controlled trials. For example, evidence for osteoporosis-related bone outcomes (Zhang 2025, He 2023, Zhang 2025b), periodontal regeneration (Zhou 2025), diabetic peripheral neuropathy (Lu 2025), and renal ischemia-reperfusion injury (Wang 2025) derives entirely from preclinical models."},{"id":"claim_24","type":"claim","text":"Several clinically important outcomes are represented by only a single study, precluding any within-corpus replication or assessment of consistency. The safety and efficacy of exosomes for knee osteoarthritis, assessed in Bolandnazar 2024 as a randomized, triple-blind, placebo-controlled trial, showed no statistically significant difference between EV-treated and placebo groups for clinical outcomes — yet this single null finding cannot be contextualized against other human trials because no other OA-specific RCT was included. Single-trial findings, whether positive or null, carry substantial uncertainty regarding reproducibility."},{"id":"claim_25","type":"claim","text":"The corpus lacks long-term mortality and hard clinical endpoint data. No included study was designed with long-term survival as a primary endpoint in the aging-relevant population. The mechanism-to-clinic gap therefore remains wide: while preclinical data convincingly demonstrate anti-inflammatory and regenerative properties of EVs (Zhu 2025, Hong 2025), the translation to clinically meaningful, sustained benefit in older adults is not established by the available human evidence."},{"id":"claim_26","type":"claim","text":"For exosomes extracellular vesicles, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support exosomes extracellular vesicles as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging."},{"id":"claim_27","type":"claim","text":"This synthesis maps 56 included sources on Extracellular vesicles across 7 outcome classes and 668 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit."},{"id":"claim_28","type":"claim","text":"Across 56 curated reference papers, the evidence base for Extracellular vesicles shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: immune. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Extracellular vesicles anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."},{"id":"claim_29","type":"claim","text":"Additional corpus sources included animal/preclinical evidence; the strongest unresolved contrast is the disagreement between Pineiro-Ramil 2025 and Hong 2025 on immune (severity 4/5), which defines the boundary condition future studies must test rather than smooth over."},{"id":"claim_30","type":"claim","text":"Additional corpus sources included animal/preclinical evidence; prior reviews in the corpus (Wu 2025, Wang 2025, Hong 2025, Wang 2025b, Su 2024) emphasize convergent signals on Extracellular vesicles. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary."},{"id":"source_1","type":"source","study":"Jafarzadeh 2025","year":2025,"doi":"10.1186/s13287-025-04592-z","url":"https://doi.org/10.1186/s13287-025-04592-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_2","type":"source","study":"Leung 2025","year":2025,"doi":"10.1186/s12882-025-04196-y","url":"https://doi.org/10.1186/s12882-025-04196-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Bolandnazar 2024","year":2024,"doi":"10.1186/s12891-024-07979-w","url":"https://doi.org/10.1186/s12891-024-07979-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Wu 2025","year":2025,"doi":"10.1186/s13287-025-04644-4","url":"https://doi.org/10.1186/s13287-025-04644-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_5","type":"source","study":"Kishta 2025","year":2025,"doi":"10.1186/s13287-025-04690-y","url":"https://doi.org/10.1186/s13287-025-04690-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_6","type":"source","study":"Behrangi 2026","year":2026,"doi":"10.1186/s13287-026-05016-2","url":"https://doi.org/10.1186/s13287-026-05016-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_7","type":"source","study":"Zhu 2025","year":2025,"doi":"10.1186/s12967-024-05744-0","url":"https://doi.org/10.1186/s12967-024-05744-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_8","type":"source","study":"Lu 2025","year":2025,"doi":"10.1186/s13287-025-04432-0","url":"https://doi.org/10.1186/s13287-025-04432-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_9","type":"source","study":"Delen 2024","year":2024,"doi":"10.1002/jev2.12458","url":"https://doi.org/10.1002/jev2.12458","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_10","type":"source","study":"Wang 2025","year":2025,"doi":"10.3389/fphar.2025.1653907","url":"https://doi.org/10.3389/fphar.2025.1653907","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_11","type":"source","study":"Zhou 2025","year":2025,"doi":"10.1186/s13018-024-05403-6","url":"https://doi.org/10.1186/s13018-024-05403-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_12","type":"source","study":"He 2023","year":2023,"doi":"10.1186/s13287-023-03317-4","url":"https://doi.org/10.1186/s13287-023-03317-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_13","type":"source","study":"Ahmed 2024","year":2024,"doi":"10.1007/s12015-023-10675-2","url":"https://doi.org/10.1007/s12015-023-10675-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_14","type":"source","study":"Dhaliwal 2026","year":2026,"doi":"10.1111/jocd.70881","url":"https://doi.org/10.1111/jocd.70881","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_15","type":"source","study":"Hong 2025","year":2025,"doi":"10.1007/s12015-025-10852-5","url":"https://doi.org/10.1007/s12015-025-10852-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_16","type":"source","study":"Luo 2024","year":2024,"doi":"10.1186/s13048-024-01489-y","url":"https://doi.org/10.1186/s13048-024-01489-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_17","type":"source","study":"Shi 2021","year":2021,"doi":"10.1002/jev2.12134","url":"https://doi.org/10.1002/jev2.12134","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_18","type":"source","study":"Wang 2025b","year":2025,"doi":"10.3389/fphar.2025.1588841","url":"https://doi.org/10.3389/fphar.2025.1588841","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_19","type":"source","study":"Pineiro-Ramil 2025","year":2025,"doi":"10.1186/s13287-025-04135-6","url":"https://doi.org/10.1186/s13287-025-04135-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_20","type":"source","study":"Wei 2026","year":2026,"doi":"10.3389/fbioe.2026.1749916","url":"https://doi.org/10.3389/fbioe.2026.1749916","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_21","type":"source","study":"Zhang 2024","year":2024,"doi":"10.1186/s12890-024-02910-4","url":"https://doi.org/10.1186/s12890-024-02910-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_22","type":"source","study":"Andrews 2025","year":2025,"doi":"10.1158/1078-0432.CCR-24-3027","url":"https://doi.org/10.1158/1078-0432.CCR-24-3027","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_23","type":"source","study":"Bozbas 2024","year":2024,"doi":"10.1016/j.ajcnut.2024.03.008","url":"https://doi.org/10.1016/j.ajcnut.2024.03.008","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_24","type":"source","study":"Zhang 2025","year":2025,"doi":"10.3389/fendo.2025.1625969","url":"https://doi.org/10.3389/fendo.2025.1625969","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_25","type":"source","study":"Zamanian 2024","year":2024,"doi":"10.1002/jev2.12492","url":"https://doi.org/10.1002/jev2.12492","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_26","type":"source","study":"Kalluri 2025","year":2025,"doi":"10.1038/s41467-025-63718-2","url":"https://doi.org/10.1038/s41467-025-63718-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_27","type":"source","study":"Chernoff 2026","year":2026,"doi":"10.1093/asj/sjaf163","url":"https://doi.org/10.1093/asj/sjaf163","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_28","type":"source","study":"Johnson 2023","year":2023,"doi":"10.1002/jev2.12332","url":"https://doi.org/10.1002/jev2.12332","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_29","type":"source","study":"Jeppesen 2025","year":2025,"doi":"10.1038/s41556-025-01621-0","url":"https://doi.org/10.1038/s41556-025-01621-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_30","type":"source","study":"Zhang 2025b","year":2025,"doi":"10.1371/journal.pone.0327011","url":"https://doi.org/10.1371/journal.pone.0327011","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_31","type":"source","study":"Santos 2026","year":2026,"doi":"10.3390/ijms27062787","url":"https://doi.org/10.3390/ijms27062787","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_32","type":"source","study":"Ye 2024","year":2024,"doi":"10.3389/fnmol.2024.1448777","url":"https://doi.org/10.3389/fnmol.2024.1448777","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_33","type":"source","study":"Akhlaghpasand 2024","year":2024,"doi":"10.1186/s13287-024-03868-0","url":"https://doi.org/10.1186/s13287-024-03868-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_34","type":"source","study":"Fang 2025","year":2025,"doi":"10.1186/s12931-025-03330-6","url":"https://doi.org/10.1186/s12931-025-03330-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_35","type":"source","study":"Kabatas 2025","year":2025,"doi":"10.5492/wjccm.v14.i4.103782","url":"https://doi.org/10.5492/wjccm.v14.i4.103782","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_36","type":"source","study":"Grueso-Navarro 2025","year":2025,"doi":"10.3390/ijms26020639","url":"https://doi.org/10.3390/ijms26020639","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_37","type":"source","study":"Habibi 2025","year":2025,"doi":"10.1186/s12886-025-04078-9","url":"https://doi.org/10.1186/s12886-025-04078-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_38","type":"source","study":"Wang 2025c","year":2025,"doi":"10.1186/s12967-025-06623-y","url":"https://doi.org/10.1186/s12967-025-06623-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_39","type":"source","study":"Hyun 2025","year":2025,"doi":"10.1002/jev2.70141","url":"https://doi.org/10.1002/jev2.70141","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_40","type":"source","study":"Estupinan 2025","year":2025,"doi":"10.1111/jocd.70208","url":"https://doi.org/10.1111/jocd.70208","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_41","type":"source","study":"Pan 2025","year":2025,"doi":"10.3389/fphar.2025.1707784","url":"https://doi.org/10.3389/fphar.2025.1707784","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_42","type":"source","study":"Doi 2025","year":2025,"doi":"10.3390/biom15121663","url":"https://doi.org/10.3390/biom15121663","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_43","type":"source","study":"Niu 2026","year":2026,"doi":"10.3389/fbinf.2025.1690932","url":"https://doi.org/10.3389/fbinf.2025.1690932","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_44","type":"source","study":"Civelek 2024","year":2024,"doi":"10.4252/wjsc.v16.i1.19","url":"https://doi.org/10.4252/wjsc.v16.i1.19","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_45","type":"source","study":"Zhu 2022","year":2022,"doi":"10.1186/s13287-022-02900-5","url":"https://doi.org/10.1186/s13287-022-02900-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_46","type":"source","study":"Li 2025","year":2025,"doi":"10.1038/s41392-025-02262-3","url":"https://doi.org/10.1038/s41392-025-02262-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_47","type":"source","study":"Su 2024","year":2024,"doi":"10.1016/j.neuroscience.2024.10.018","url":"https://doi.org/10.1016/j.neuroscience.2024.10.018","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_48","type":"source","study":"Zeng 2025","year":2025,"doi":"10.3389/fimmu.2025.1613716","url":"https://doi.org/10.3389/fimmu.2025.1613716","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_49","type":"source","study":"Ghanem 2025","year":2025,"doi":"10.3389/fphar.2025.1622280","url":"https://doi.org/10.3389/fphar.2025.1622280","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_50","type":"source","study":"Svolacchia 2024","year":2024,"doi":"10.3390/medicina60040670","url":"https://doi.org/10.3390/medicina60040670","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_51","type":"source","study":"Mitra 2026","year":2026,"doi":"10.1002/mnfr.70397","url":"https://doi.org/10.1002/mnfr.70397","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_52","type":"source","study":"Zhong 2023","year":2023,"doi":"10.1186/s13287-023-03409-1","url":"https://doi.org/10.1186/s13287-023-03409-1","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_53","type":"source","study":"Vreones 2022","year":2022,"doi":"10.1111/acel.13754","url":"https://doi.org/10.1111/acel.13754","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_54","type":"source","study":"Dai 2026","year":2026,"doi":"10.1097/MD.0000000000046948","url":"https://doi.org/10.1097/MD.0000000000046948","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_55","type":"source","study":"Su 2025","year":2025,"doi":"10.3389/fphar.2025.1617874","url":"https://doi.org/10.3389/fphar.2025.1617874","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_56","type":"source","study":"Antoniewicz 2024","year":2024,"doi":"10.1007/s12012-024-09934-6","url":"https://doi.org/10.1007/s12012-024-09934-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_1","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_2","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_3","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_4","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_5","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_6","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_7","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_8","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_9","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_10","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_11","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_12","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_13","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_14","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_15","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_16","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_17","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_18","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_19","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_20","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_21","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_22","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_23","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_24","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_25","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_26","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_27","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_28","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_29","type":"contains_claim"},{"from":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","to":"claim_30","type":"contains_claim"}],"screening":{"identified":56,"screened":56,"excluded":0,"included":56,"included_or_retained":56,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"56 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","screening":{"identified":56,"screened":56,"excluded":0,"included":56,"included_or_retained":56,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"56 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The conclusion is that exosomes extracellular vesicles should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","7 included sources were assigned to this outcome class. Directional coding: mixed=2, negative=1, null=2, unclear=2. Directness coding: indirect=2, mechanistic=1, review=4.","Several clinically important outcomes are represented by only a single study, precluding any within-corpus replication or assessment of consistency. The safety and efficacy of exosomes for knee osteoarthritis, assessed in Bolandnazar 2024 as a randomized, triple-blind, placebo-controlled trial, showed no statistically significant difference between EV-treated and placebo groups for clinical outcomes — yet this single null finding cannot be contextualized against other human trials because no other OA-specific RCT was included. Single-trial findings, whether positive or null, carry substantial uncertainty regarding reproducibility.","The corpus lacks long-term mortality and hard clinical endpoint data. No included study was designed with long-term survival as a primary endpoint in the aging-relevant population. The mechanism-to-clinic gap therefore remains wide: while preclinical data convincingly demonstrate anti-inflammatory and regenerative properties of EVs (Zhu 2025, Hong 2025), the translation to clinically meaningful, sustained benefit in older adults is not established by the available human evidence.","For exosomes extracellular vesicles, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support exosomes extracellular vesicles as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 56 curated reference papers, the evidence base for Extracellular vesicles shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: immune. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Extracellular vesicles anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nJafarzadeh 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nLeung 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nBolandnazar 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nWu 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nKishta 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nBehrangi 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nZhu 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nLu 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nDelen 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nWang 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nZhou 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nHe 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nAhmed 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nDhaliwal 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nHong 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nLuo 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nShi 2021,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nWang 2025b,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nPineiro-Ramil 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nWei 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nZhang 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nAndrews 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nBozbas 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nZhang 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nZamanian 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nKalluri 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nChernoff 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nJohnson 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nJeppesen 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nZhang 2025b,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSantos 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nYe 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nAkhlaghpasand 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nFang 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nKabatas 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nGrueso-Navarro 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nHabibi 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nWang 2025c,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nHyun 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nEstupinan 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nPan 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nDoi 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nNiu 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nCivelek 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nZhu 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLi 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSu 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nZeng 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nGhanem 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSvolacchia 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nMitra 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nZhong 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nVreones 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nDai 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSu 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nAntoniewicz 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"3fa5cd13-7439-4f62-b446-2c8e84c03e7e","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Jafarzadeh 2025","doi":"10.1186/s13287-025-04592-z","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Leung 2025","doi":"10.1186/s12882-025-04196-y","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Bolandnazar 2024","doi":"10.1186/s12891-024-07979-w","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Wu 2025","doi":"10.1186/s13287-025-04644-4","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Kishta 2025","doi":"10.1186/s13287-025-04690-y","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Behrangi 2026","doi":"10.1186/s13287-026-05016-2","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Zhu 2025","doi":"10.1186/s12967-024-05744-0","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Lu 2025","doi":"10.1186/s13287-025-04432-0","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Delen 2024","doi":"10.1002/jev2.12458","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Wang 2025","doi":"10.3389/fphar.2025.1653907","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Zhou 2025","doi":"10.1186/s13018-024-05403-6","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"He 2023","doi":"10.1186/s13287-023-03317-4","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Ahmed 2024","doi":"10.1007/s12015-023-10675-2","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Dhaliwal 2026","doi":"10.1111/jocd.70881","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Hong 2025","doi":"10.1007/s12015-025-10852-5","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Luo 2024","doi":"10.1186/s13048-024-01489-y","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Shi 2021","doi":"10.1002/jev2.12134","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Wang 2025b","doi":"10.3389/fphar.2025.1588841","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Pineiro-Ramil 2025","doi":"10.1186/s13287-025-04135-6","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Wei 2026","doi":"10.3389/fbioe.2026.1749916","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Zhang 2024","doi":"10.1186/s12890-024-02910-4","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Andrews 2025","doi":"10.1158/1078-0432.CCR-24-3027","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Bozbas 2024","doi":"10.1016/j.ajcnut.2024.03.008","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Zhang 2025","doi":"10.3389/fendo.2025.1625969","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Zamanian 2024","doi":"10.1002/jev2.12492","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Kalluri 2025","doi":"10.1038/s41467-025-63718-2","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Chernoff 2026","doi":"10.1093/asj/sjaf163","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Johnson 2023","doi":"10.1002/jev2.12332","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Jeppesen 2025","doi":"10.1038/s41556-025-01621-0","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Zhang 2025b","doi":"10.1371/journal.pone.0327011","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Santos 2026","doi":"10.3390/ijms27062787","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Ye 2024","doi":"10.3389/fnmol.2024.1448777","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Akhlaghpasand 2024","doi":"10.1186/s13287-024-03868-0","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Fang 2025","doi":"10.1186/s12931-025-03330-6","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Kabatas 2025","doi":"10.5492/wjccm.v14.i4.103782","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Grueso-Navarro 2025","doi":"10.3390/ijms26020639","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Habibi 2025","doi":"10.1186/s12886-025-04078-9","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Wang 2025c","doi":"10.1186/s12967-025-06623-y","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Hyun 2025","doi":"10.1002/jev2.70141","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Estupinan 2025","doi":"10.1111/jocd.70208","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Pan 2025","doi":"10.3389/fphar.2025.1707784","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Doi 2025","doi":"10.3390/biom15121663","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Niu 2026","doi":"10.3389/fbinf.2025.1690932","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Civelek 2024","doi":"10.4252/wjsc.v16.i1.19","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Zhu 2022","doi":"10.1186/s13287-022-02900-5","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Li 2025","doi":"10.1038/s41392-025-02262-3","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Su 2024","doi":"10.1016/j.neuroscience.2024.10.018","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Zeng 2025","doi":"10.3389/fimmu.2025.1613716","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Ghanem 2025","doi":"10.3389/fphar.2025.1622280","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Svolacchia 2024","doi":"10.3390/medicina60040670","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Mitra 2026","doi":"10.1002/mnfr.70397","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Zhong 2023","doi":"10.1186/s13287-023-03409-1","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Vreones 2022","doi":"10.1111/acel.13754","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Dai 2026","doi":"10.1097/MD.0000000000046948","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Su 2025","doi":"10.3389/fphar.2025.1617874","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Antoniewicz 2024","doi":"10.1007/s12012-024-09934-6","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}}]}